** Shares of drugmaker Sage Therapeutics SAGE.O rise 36.4% to $7.57 premarket
** Drugmaker Biogen BIIB.O will buy all outstanding shares of Sage that it does not already own for $7.22 apiece, a filing showed on Friday
** The offer price, representing a 30% premium to stock's close on Friday, values Sage's equity at $441.7 mln, according to Reuters calculations
** Brokerage William Blair says the offer is prudent to maximize potential for Sage and Biogen's depression drug, Zurzuvae, without materially impacting Biogen's M&A deal capacity
** Up to last close, stock down 78.1% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。